智飞生物：带状疱疹mRNA疫苗已经获得药物临床试验申请受理通知书

Core Viewpoint - The company is actively developing multiple vaccine technology platforms, including mRNA and novel adjuvant technologies, to achieve innovation and upgrades in vaccine products [2] Group 1 - The company has established an mRNA technology platform and a novel adjuvant technology platform [2] - The company’s subsidiary, Zhifei Longkema, has received a clinical trial acceptance notice from the National Medical Products Administration for its shingles mRNA vaccine [2] - The company aims to explore various vaccine development pathways for iterative upgrades and breakthroughs in vaccine products [2]